Pharming Group N.V. - ADS, each representing 10 ordinary shares (PHAR)

Pharming Group (NASDAQ:PHAR) reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema therapy RUCONEST. The company reduced its full-year revenue outlook by $30 million but said it expects RU

Pharming Group (NASDAQ:PHAR) executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company’s planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.

Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of TK-D2C AI Robots.

Pharming's Phase 3 trial results for leniolisib in children with APDS demonstrate efficacy and safety, supporting future regulatory filings in 2025.

Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!